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The bacterium Clostridium difficile is the leading cause of healthcare 
associated diarrhoea in the developed 
world and thus presents a major finan-
cial burden. The main virulence fac-
tors of C. difficile are two large toxins, 
A and B. Over the years there has been 
some debate over the respective roles 
and importance of these two toxins. To 
address this, we recently constructed 
stable toxin mutants of C. difficile and 
found that they were virulent if either 
toxin A or toxin B was functional. This 
underlined the importance of each toxin 
and the necessity to consider both when 
developing countermeasures against 
Clostridium difficile infection (CDI). 
In this article we discuss our findings in 
the context of previous work and outline 
some of the challenges which face the 
field as a result.
Introduction
In recent years Clostridium difficile infec-
tion (CDI) has emerged as the leading 
cause of healthcare associated diarrhoea 
in the developed world. The endospores 
of this Gram-positive anaerobe are widely 
distributed in the environment and their 
ingestion by hospitalised patients with a 
disrupted gut microflora, a common con-
sequence of antibiotic treatment, leads to 
colonisation and subsequent disease.1-3 
The clinical symptoms of CDI can range 
from asymptomatic carriage to a mild self-
limiting or severe diarrhoea which may 
progress to the potentially fatal condi-
tions of pseudomembranous colitis and/
or toxic megacolon. In most developed 
countries, the incidence of CDI continues 
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to increase, concomitant with the emer-
gence of so-called ‘hyper-virulent’ strains, 
responsible for increased severity of CDI 
and a rise in fatalities. In England and 
Wales, for example, where the mortal-
ity rates attributable to CDI are appar-
ently falling, C. difficile still killed almost 
4,000 people in 2009 alone. This upsurge 
in the incidence of CDI has placed a large 
financial burden on healthcare systems 
worldwide.2
Toxin A and Toxin B in Disease
Two main virulence factors, toxin A and 
toxin B, have been described for C. difficile. 
The two encoding genes, tcdA and tcdB, 
respectively, form part of a well defined 
pathogenicity locus (PaLoc) (Fig. 1). The 
locus also encompasses three ancillary 
genes. The tcdR gene encodes an alterna-
tive sigma factor (TcdR) responsible for the 
transcription of tcdA and tcdB.4,5 A second 
gene tcdC, is suggested to encode an anti-
sigma factor (TcdC) which represses toxin 
production by directly interacting with 
TcdR or TcdR-containing RNA poly-
merase.6 The third gene, tcdE, codes for a 
protein (TcdE) which shares similarity to 
phage holin proteins, and may be involved 
in toxin secretion.7 The entire PaLoc 
element is 19.6 kb in size and, therefore, 
represents an investment by the organism 
in terms of its continued maintenance in 
the genome (Fig. 1).
The function of the toxins themselves 
has been studied extensively and their 
mode of action is now well understood. 
Both are cytotoxic and belong to the fam-
ily of large clostridial toxins, capable of 
inactivating Rho-GTPases and leading to 
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system, one of its major strengths is that 
the mutants generated are stable. Thus, 
excision of the inserted segment of DNA is 
predicted, and indeed was experimentally 
verified,25,26 not to occur.
Mutants of C. difficile Made  
by Recombination
The first isogenic toxin mutants of C. dif-
ficile were made using homologous recom-
bination.22 Two mutants were constructed, 
an A-B+ and a corresponding A-B+. 
Following the phenotypic characteriza-
tion of both mutants, their pathogenicity 
was tested in the hamster infection model. 
Whilst the parental strain (A+B+) and the 
A-B+ single mutant caused disease, the 
A+B- single mutant did not. The authors 
concluded that toxin B alone was essen-
tial to disease. This observation caused a 
paradigm shift in the perception of the 
relative roles of the two toxins. Crucially, 
these conclusions had major implications 
to the development of medical counter-
measures, both in terms of diagnosis and 
therapeutics.
Mutants of C. difficile Made  
by ClosTron Technology
Given the major ramifications of the above 
study, we set out to replicate its findings 
through the creation of equivalent, stable 
mutants of the same strain of C. diffi-
cile using ClosTron technology.27 In this 
instance, we were also able to generate 
the control of a toxin A-B- double mutant, 
the first ever reported for C. difficile, in 
addition to single A+B- and A-B+ mutants. 
The authenticity of the mutants was con-
firmed at both the DNA and phenotypic 
level. In the latter respect, the results con-
curred with those obtained by Lyras et 
al.21 Additionally, the double A-B- mutant 
was shown to be devoid of the ability to 
produce cytotoxic activity. Having con-
firmed the expected phenotypes of the 
three mutants, we went on to perform in 
vivo analysis using the hamster model of 
infection. In agreement with the previous 
study, all hamsters infected with the A+B+ 
and A-B+ mutants strains succumbed to 
CDI within 1–1.3 days. In contrast, how-
ever, all of the animals challenged with 
the A+B- mutant strain also developed 
By this stage it was clear that insight 
into the relative roles of the two toxins 
required appropriate directed mutagenesis 
technologies. These would allow the cre-
ation of isogenic mutants of A+B+ strains 
that produced one or other of the two tox-
ins and an assessment of their pathogenic 
potential in an in vivo model of infection.
Mutagenesis of C. difficile
The longstanding inability to make 
directed mutants in C. difficile was solved 
through the development of two, funda-
mentally different approaches based either 
on homologous recombination or on 
intron retargeting. The creation of inser-
tional mutants by the former approach 
was achieved using either replication defi-
cient19 or defective20 plasmids which are 
inserted into the chromosome via a single 
crossover recombination event. As such an 
event results in duplication of a region of 
DNA on either side of the inserted plas-
mid, the mutants generated are predicted 
to be unstable, as a subsequent recombina-
tion event between the duplicated DNA 
will result in plasmid excision. Indeed, 
such instability has been observed in a 
number of studies to date.20-22
In the second approach, a system was 
developed that capitalised on the ability to 
retarget the specificity of a mobile group 
II intron to virtually any desired chromo-
somal locus. Pioneered by the Lambowitz 
laboratory, this system was marketed by 
Sigma Aldrich under the brand-name 
‘TargeTron’.23 The utility in clostridia of 
a basic, marker-less targetron was first 
demonstrated in Clostridium perfringens.24 
The system first applied to C. difficile was 
termed the ClosTron,25,26 and incorpo-
rated a specialised retrotransposition-acti-
vated marker (RAM) within the group II 
intron, facilitating selection of integrants. 
Aside from the extreme rapidity and 
effectiveness of the ClosTron mutagenesis 
disorganization of the cytoskeleton and 
subsequent cell death.8,9 It is important 
to understand the relative roles of toxin 
A and B in CDI, from both a diagnos-
tic and a therapeutic perspective. In the 
1980’s the spotlight fell firmly on toxin 
A, when it was shown that the adminis-
tration of pure toxin A alone to hamsters 
caused disease, whereas toxin B alone did 
not. However, intragastric challenge of 
hamsters with toxin B did cause disease 
symptoms if prior damage to the mucosa 
had occurred through co-administration 
of sub-lethal concentrations of toxin A.10 
Moreover, co-administration of toxin B 
with toxin A resulted in more severe dis-
ease symptoms. This led to the notion 
that both toxins acted in concert to bring 
about disease symptoms, with toxin A 
bringing about the initial damage to the 
colon allowing the more potent toxin B 
access.
The isolation of variant strains which 
apparently produced no toxin A (A-B+ 
strains) from the early 1990s onwards 
presented a challenge to the established 
dogma that both toxins were required for 
disease. Whilst some of the early strains 
isolated were avirulent in the hamster 
model11 other independently isolated 
strains exhibited pathogenic potential.12 
The latter strains, however, were shown to 
produce variant toxin B, showing similar-
ity to Clostridium sordelli lethal toxin.13,14 
These toxins consist of a TcdB binding 
domain but have a changed target. They 
have been shown to be as cytotoxic as 
ordinary TcdB, however they do show a 
differential cytopathic effect in cytotox-
icity assays.14 Interestingly, the advent of 
molecular typing techniques15 has resulted 
in the isolation of an increasing number 
of A-B+ toxinotypes that do not produce 
detectable toxin A.16-18 Nonetheless, the 
vast majority of strains isolated from cases 
of CDI continued to be found to produce 
both toxin A and B.
Figure 1. the pathogenicity locus (PaLoc) of Clostridium difficile 630, comprising the two toxin 
genes tcdA and tcdB as well as three ancillary genes, tcdR, tcdE and tcdC.
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in non-selective media, and designated the 
strain 630E. Interestingly, although the 
data were not presented, it was reported to 
have undergone the same specific deletion 
of ermB as 630Δerm.20,28
It is our hypothesis that during 
repeated subculture, ancillary mutations 
have arisen which have impacted on the 
virulence potential of one or other of the 
two strains in the presence of different 
toxin gene alleles. Crude phenotypic anal-
yses support this view, as preliminary side-
by-side comparisons of the 630Δerm and 
630E have shown clear phenotypic differ-
ences. For example, whilst 630Δerm and 
the parent 630 strain are grossly indistin-
guishable, strain 630E has become non-
motile and lacks any sign of flagella when 
examined by Electron Microscopy (Baban 
S, Kuehne S and Minton N, unpublished 
data). Moreover, unlike 630 and 630Δerm, 
630E also exhibits a predilection to floccu-
late when grown in liquid culture (Kuehne 
S and Minton N, unpublished data) and 
has a more severe glucose response, affect-
ing the levels of toxin produced in the 
presence of this carbon source (Dupuy B, 
personal communication).
To resolve these differences we have 
begun a programme of work designed 
to re-sequence the genomes of all the 
strains (mutants and progenitor strains) 
involved in the two studies to identify 
the nucleotide changes that have arisen, 
and correlate their presence or absence 
with observed phenotypes, including 
virulence/avirulence. At the same time 
we are in the process of making equiva-
lent ClosTron mutants in 630E to those 
commercial suppliers, does introduce 
other possible variables. Hamsters from 
different colonies might have different 
microbiota compositions which could be 
important in terms of colonisation and 
susceptibility to CDI. Ideally, the two dif-
ferent mutants would need to be analysed 
in parallel under identical conditions at 
the same location. However, given that 
the differences in execution of the hamster 
model of infection represent an extremely 
unlikely explanation for the contradictory 
outcomes, it is difficult to justify the use of 
animals for this purpose.
The final difference between the two 
studies, and perhaps the most telling, 
relates to the strains used. Whilst the 
parent strain employed in both cases was 
C. difficile strain 630, there are funda-
mental differences between the isolates 
used. This is because mutant generation 
to date has relied on the ability to select 
resistance to erythromycin, a require-
ment that precludes the use of strain 630 
as it carries a functional genomic copy 
of ermB. In both studies, therefore, an 
independently isolated derivative strain 
of 630 was employed that was sensitive to 
this antibiotic. In our study, we used the 
strain 630Δerm, isolated in the Mullany 
laboratory (UCL, London, UK) after 30 
repeated subcultures of strain 630 in non-
selective media.28 Following its isolation, 
the acquired sensitivity of 630Δerm was 
shown to be due to a specific deletion of 
ermB. In parallel, the Lyras laboratory 
independently isolated another erythro-
mycin sensitive strain,20 through an undis-
closed number of subcultures of strain 630 
CDI, albeit over a slightly longer time-
frame (mean time to death of 4 days). As 
expected, animals infected with the dou-
ble A-B- mutant survived, demonstrating 
no symptoms of CDI (Fig. 2).
Overall, the findings of our study were 
largely in agreement with those of Lyras 
et al.21 with one notable exception. Our 
data clearly showed that an A+B- mutant 
producing toxin A alone can cause disease 
in the hamster. This latter finding re-
establishes the importance of toxin A in 
CDI, and suggests that it should remain as 
a valid target when considering any medi-
cal countermeasures.
The Relative Roles  
of Toxin A and B
In comparison to Lyras et al.21 our find-
ings created a paradox. How can two stud-
ies which generated essentially equivalent 
A+B- insertion mutants in the same strain 
of C. difficile, lead to a contradictory out-
come in the hamster model of infection? 
There are a number of factors that need to 
be considered.
As discussed, we used fundamentally 
different methods to make our respec-
tive toxin B mutants. Nonetheless, both 
mutants were generated by inserting a 
segment of DNA into the coding region 
of tcdB. Whilst not at precisely the same 
point, the site of insertion is broadly speak-
ing equivalent, residing within the cata-
lytic domain, and resulting in the same 
phenotype; that is, discernable absence 
of toxin as measured by cytotoxicity assay 
and western blots. Therefore, the method 
of mutant generation is unlikely to explain 
the differences between the two studies.
Does the answer reside with the in vivo 
infection model? As in many countries, 
the UK regulatory authorities do not allow 
the use of death as an experimental end-
point in studies carried out in vivo, as was 
used by Lyras et al.21 Therefore, we defined 
terminal CDI based on a clinical scoring 
system and used this as our experimental 
endpoint.27 Importantly, we are confident 
that the difference between our two stud-
ies does not reside here. As the studies 
were undertaken in two different loca-
tions, subtle differences in animal main-
tenance and the procedures employed, or 
the sourcing of animals from disparate 
Figure 2. Survival curves showing the days from challenging hamsters with C. difficile spores to 
endpoint. Groups of 8 hamsters were infected with the respective strains, comprising the wild 
type (A+B+), the single toxin mutants (A+B- and A-B+) and the double mutant (A-B-).
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made in 630Δerm, together with similar 
mutants in other strains of C. difficile, 
and in particular hyper-virulent strains. 
Furthermore the study of toxin mutants 
in other animal models could be consid-
ered. The mouse model is well established 
to study colonisation but has recently also 
been developed as an infection model.29 
The piglet model has also been described 
as mimicking CDI well.30
Throughout these studies, it should be 
borne in mind that while extremely use-
ful, animals are only a model of human 
disease. Findings obtained in animals 
should, therefore, be treated with a certain 
amount of caution.
Future Challenges
Further work is required to more defini-
tively define the relative role of toxin A 
and B in CDI. It is noteworthy that 
the majority of C. difficile strains iso-
lated to date carry a functional PaLoc 
and thus produce both toxin A and B. 
The notion of continued pressure for its 
presence in the C. difficile population is 
implicit. What might this selective pres-
sure be? Simplistically, the symptoms of 
CDI (diarrhoea) lead to more effective 
transmission of the organism through 
dispersal of spores. By implication, this is 
most efficient in organisms that produce 
toxin A and B, ensuring both toxins are 
normally present. Nonetheless, strains 
which produce only one of the toxins have 
arisen. This includes an isolated report of 
an A+B- strain associated with relapse,31 as 
well as the more numerous examples of 
the isolation of A-B+ strains.12,16,17,32 The 
continued pathogenic potential of these 
variant strains, despite the loss of the 
capability to produce both toxins, needs 
to be investigated further to ascertain 
whether ancillary factors counter the loss 
of a toxin. For instance, is the toxin B that 
is produced by naturally occurring A-B+ 
strains equivalent to that produced by 
A+B+ strains, or has the cytotoxic poten-
tial of toxin B been altered, as in strains 
8,86433 and 1,47013? Furthermore, what 
contribution, if any, does the presence of 
the binary toxin, CDT, have in naturally 
occurring A-B+ strains?
In the meantime, it remains impor-
tant to consider both toxin A and toxin 
